Povetacicept

普维他西普

Report date: 2026/05/20 20:02:01

Base Information

Drug NamePovetacicept
Drug Alias NameALPN-303ALPN 30x
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 inhibitorsB-cell-activating factor/B lymphocyte stimulator inhibitors
TargetsTumor necrosis factor ligand superfamily member 13B-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsCytopeniaInflammationLupus Erythematosus, Systemic +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAlpine Immune Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesZai Lab (Shanghai) Co LtdAlpine Immune Sciences IncVertex Pharmaceuticals Incorporated +[5] 
Inactive CompaniesN/A
Active IndicationsCytopeniaInflammationLupus Erythematosus, Systemic +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A